Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based chemotherapy (taxotere or cabazitaxel). The actual texts of the results are published in today’s issue of the New England Journal of Medicine.
Of course, there were no surprises, but it is good to see them in black and white. To sum up the results:
• The most important was that the overall survival of men in the abiraterone plus prednisone arm of the trial (14.8 months) was longer than that of men in the placebo plus prednisone arm (10.9 months) (hazard ratio